Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NuQu
- Development stage
- Unknown
- Lead developer
- ISTO Biologics
- Modality
- Cell Therapies
- Administration
- Intradiscal
01
Overview
NuQu is a cell-based therapy developed by ISTO Technologies for the treatment of painful spinal disc conditions. It was investigated in clinical trials as a novel regenerative approach targeting intervertebral disc degeneration, aiming to alleviate pain and restore function. The therapy involves the injection of cells into degenerated spinal discs to promote tissue repair and regeneration. NuQu is not an approved pharmaceutical product; it has been studied in clinical trials for spine-related indications but does not have established regulatory approval or widespread commercial availability.
- Brand names
- NuQu
Beyond the preview
Go deeper on NuQu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuQu.